2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: ON

Poster-Quality of Life and Outcomes

October 25, 2021

Understanding Health and Well-Being of Women with MS: Implications for Health Care Providers

Background: Multiple Sclerosis (MS) is a debilitating neurological disease that is three times more likely to impact women. Gender is a key...

Read More →

Poster-Psychosocial Factors

October 25, 2021

Cognitive Fatigability and Cardiorespiratory Fitness in Persons with Advanced Multiple Sclerosis

Background: Fatigue, both physical and cognitive, is one of the most prevalent and disabling symptoms experienced by persons with multiple...

Read More →

Poster-Psychosocial Factors

October 25, 2021

A Continuum of Languishing to Flourishing: A Qualitative Study of Psychological Resilience in Multiple Sclerosis Family Caregivers

Background: Informal unpaid family caregivers (e.g., spouses, parents, siblings) are the primary providers of support to people living with...

Read More →

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

October 25, 2021

Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases

Background: Little is known about the stability of the gut microbiota in multiple sclerosis (MS) over time. Objectives: To determine if the...

Read More →

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

October 25, 2021

Validation of Paced Auditory Serial Addition Test (PASAT) Regression Normative Data for Performance and Cognitive Fatigability in Multiple Sclerosis

Background: Cognitive fatigability (CF) can be defined as an objective decline in performance that occurs over time during sustained...

Read More →

Poster-Family and Caregivers

October 25, 2021

Profiles of Resilience Among MS Care Partners

Background: Psychological resilience may play an important role in protecting multiple sclerosis (MS) care-partners from the negative...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC